Literature DB >> 31567278

Predictors of Outcome in Mammary Adenoid Cystic Carcinoma: A Multi-Institutional Study.

Elzbieta Slodkowska1, Bin Xu1, Zuzana Kos2, Anita Bane3, Maja Barnard1,4, Judit Zubovits1,5, Pratibha Iyengar1,6, Hala Faragalla1,7, Dmitry Turbin8, Phillip Williams9, Penny J Barnes10, Anna Marie Mulligan1,11.   

Abstract

Mammary adenoid cystic carcinoma (ACC) is a rare subtype of breast cancer with a favorable prognosis. Here we report on predictors of outcome based on a detailed morphologic review and analysis of 108 mammary ACC. Sixty-four tumors (59.2%) were pure conventional ACC, 23 (21.3%) were pure basaloid ACC. Follow-up was available for 87 patients (median: 51 mo). Eighteen patients (20.7%) developed recurrence: 7 (8%) had local recurrence and 14 (16%) had distant metastasis. Two patients died of disease, 1 died of an unrelated cause, 14 were alive with disease (including 8 in palliative care), and 70 (80.5%) were alive with no evidence of disease. Of 90 patients with known lymph node (LN) status 9 (10%) had nodal involvement (all with basaloid ACC). Distant metastases in patients with predominantly basaloid ACC compared with pure conventional ACC were more common (40% vs. 7.7%) and occurred earlier (22 vs. 84 mo). The following factors were found to be predictive of recurrence-free survival: positive margin, Nottingham grade, neovascularization, basaloid component, perineural invasion, lymphovascular invasion, >30% solid growth, necrosis and LN involvement; the first 3 remained statistically significant on multivariate analysis. Factors predictive of distant disease-free survival were neovascularization, Nottingham grade, lymphovascular invasion, solid component >50%, LN involvement, basaloid component >50%, tumor necrosis, perineural invasion, and final margin. Only neovascularization remained statistically significant on multivariate analysis. Basaloid ACC is an aggressive variant of mammary ACC with more frequent nodal involvement and higher incidence of distant spread. LN staging should be performed for all mammary basaloid ACC.

Entities:  

Mesh:

Year:  2020        PMID: 31567278     DOI: 10.1097/PAS.0000000000001378

Source DB:  PubMed          Journal:  Am J Surg Pathol        ISSN: 0147-5185            Impact factor:   6.394


  7 in total

1.  The clinical behavior and genomic features of the so-called adenoid cystic carcinomas of the solid variant with basaloid features.

Authors:  Christopher J Schwartz; Edi Brogi; Antonio Marra; Arnaud F Da Cruz Paula; Gouri J Nanjangud; Edaise M da Silva; Sujata Patil; Shreena Shah; Katia Ventura; Pedram Razavi; Larry Norton; Timothy D'alfonso; Britta Weigelt; Fresia Pareja; Jorge S Reis-Filho; Hannah Y Wen
Journal:  Mod Pathol       Date:  2021-10-01       Impact factor: 8.209

2.  Distinct clinicopathological and genomic features in solid and basaloid adenoid cystic carcinoma of the breast.

Authors:  Juan Ji; Fang Zhang; Fanglei Duan; Hong Yang; Jun Hou; Yang Liu; Jie Dai; Qiong Liao; Xian Chen; Qingsong Liu
Journal:  Sci Rep       Date:  2022-05-19       Impact factor: 4.996

Review 3.  Problematic breast tumors reassessed in light of novel molecular data.

Authors:  Fresia Pareja; Britta Weigelt; Jorge S Reis-Filho
Journal:  Mod Pathol       Date:  2020-10-06       Impact factor: 7.842

4.  Male Adenoid Cystic Carcinoma of the Breast.

Authors:  Jie Xiao Li; Xi Meng Zhang; Yun Xiao Xiao; Zi Mei Tang; Tao Huang; Jie Ming
Journal:  J Med Cases       Date:  2021-12-02

5.  Adenoid Cystic Carcinoma of the Breast in a Male Patient: A Case Report and Literature Review.

Authors:  Dan Wan; Hongyuan Zhou; Yutao Zhang
Journal:  Front Oncol       Date:  2022-07-07       Impact factor: 5.738

6.  Adenoid Cystic Carcinoma of the Breast May Be Exempt from Adjuvant Chemotherapy.

Authors:  Lixi Li; Di Zhang; Fei Ma
Journal:  J Clin Med       Date:  2022-07-31       Impact factor: 4.964

7.  Solid-basaloid variant of adenoid cystic carcinoma of the breast with near complete response to neoadjuvant chemotherapy.

Authors:  Anne Grabenstetter; Edi Brogi; Hong Zhang; Pedram Razavi; Jorge S Reis-Filho; Kimberly J VanZee; Larry Norton; Hannah Y Wen
Journal:  NPJ Breast Cancer       Date:  2022-08-11
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.